A phase 1b pharmacokinetic-pharmacodynamic-pharmacogenomic study of enzastaurin in patients with B-cell chronic lymphocytic leukemia (B-CLL)

Trial Profile

A phase 1b pharmacokinetic-pharmacodynamic-pharmacogenomic study of enzastaurin in patients with B-cell chronic lymphocytic leukemia (B-CLL)

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Nov 2013

At a glance

  • Drugs Enzastaurin (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Pharmacodynamics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 22 Nov 2013
    • 24 Mar 2009 Actual patient number (18) added as reported by ClinicalTrials.gov.
    • 24 Mar 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top